Efficacy and safety of ombitasvir/paritaprevir/ritonavir, ledipasvir/sofosbuvir, elbasvir /grazoprevir, glecaprevir/pibrentasvir after curative treatment of HCV-Related HCC - Prospective multicenter-cooperative cohort study
Not Applicable
Recruiting
- Conditions
- HCV-related hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000025085
- Lead Sponsor
- Juntendo University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who have a history of hypersensitivity to Omvitasvir/paritaprevir/ritonavir 2)Patients who are excluded from HCV eradication therapy because of decompensated cirrhosis and others 3)Patients who cannot receive IFN-free therapy because of concomitant medication etc. 4)Women who are or may be pregnant 5)Patients considered to be ineligible for participation in the study by the investigator or subinvestigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Eradication ratio of HCV 24 weeks after treatment
- Secondary Outcome Measures
Name Time Method Adverse events and side effects Recurrence of HCC